基于中医传承辅助平台与网络药理学探析《中华人民共和国药典》中含生石膏成方制剂的证治规律及作用机制  

Exploration of the Syndrome and Treatment Law and Mechanism of Formulated Preparations Containing Shengshigao(Gypsum Crudum)in the Pharmacopoeia of the People's Republic of China Based on the Traditional Chinese Medicine Inheritance Assistance Platform and Network Pharmacology

作　　者：李宝赢 查玉玲 邓秘 牛露娜 李雪菲 朱若维[1] 荆鲁 LI Baoying;ZHA Yuling;DENG Mi;NIU Luna;LI Xuefei;ZHU Ruowei;JING Lu(Eye Hospital China Academy of Chinese Medical Sciences,Beijing 100040,China;Postdoctoral Mobile Station of China Academy of Chinese Medical Sciences,Beijing 100700,China)

机构地区：[1]中国中医科学院眼科医院,北京100040 [2]中国中医科学院博士后流动站,北京100700

出　　处：《中医药导报》2024年第5期145-150,172,共7页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：中国中医科学院中央级公益性科研院所基本科研业务费(ZZ15-XY-LCQ-07);国家自然科学基金面上项目(81274181)。

摘　　要：目的:研究2020年版《中华人民共和国药典》中含生石膏成方制剂的证治规律及作用机制。方法:将符合纳入、排除标准的成方制剂录入中医传承辅助平台,并基于中医传承辅助平台的频率统计、关联规则与聚类算法功能,探析含生石膏成方制剂的配伍原则、组方规律及新方组合,并提取核心用药;同时采用网络药理学方法,对证治规律研究中所筛选的主要中医疾病进行生石膏作用机制研究。结果:最终共纳入50条含生石膏成方制剂,涉及肺咳、肺炎喘嗽、感冒等中医疾病24种,痰热壅肺、肺经风热、热毒内盛等适宜证型22项,生石膏、甘草、黄芩、杏仁、麻黄等中药170味,同时提取“生石膏-甘草”“生石膏-黄芩”等核心药对4项,“生石膏-五味子-枳实-桔梗-桑白皮”等新方组合7条,以及“生石膏、麻黄、甘草、杏仁、黄芩、桔梗、陈皮”等核心用药6组;并筛选获得ALB、IL-1B、1L-6等“生石膏-主要中医疾病”交集靶点18个,以及肿瘤坏死因子(TNF)、白细胞介素-17(IL-17)、缺氧诱导因子-1(HIF-1)等主要信号通路3条。结论:2020年版《中华人民共和国药典》中含生石膏成方制剂主要以麻杏石甘汤为基础方化裁,其机制可能与生石膏抑制TNF、IL-17、HIF-1等信号通路,下调炎症反应过程,减少促炎因子释放有关。Objective:To study the syndrome and treatment law and mechanism of formulated preparations containing Shengshigao(Gypsum Crudum)in the 2020 edition of the Pharmacopoeia of the People's Republic of China.Method:The formulated preparations meeting the inclusion and exclusion criteria were recorded into the traditional Chinese medicine inheritance assistance platform(TCMIAP).Based on the frequency statistics,association rules and clustering algorithm functions of the TCMIAP,the compatibility principle,prescription formation law and new prescription combination of the formulated preparations containing Shengshigao(Gypsum Crudum)were analyzed,and the core drugs were extracted.At the same time,the network pharmacology method was used to study the mechanism of gypsum action in the main traditional Chinese medcine(TCM)diseases screened in the study of syndrome and treatment.Result:A total of 50 formulated preparations containing gypsum were ultimately included,involving 24 TCM diseases such as pulmonary cough,pneumonia and asthma,and common cold,and 22 suitable syndrome type such as phlegm heat obstructing the lung,wind heat in the lung meridian,and heat toxin internal accumulation.There were 170 traditional Chinese Medicine such as Shengshigao(Gypsum Crudum),Gancao(Glycyrrhizae Radix),Huangqin(Scutellariae Radix)Xingren(Armeniacae Semen),and Mahuang(Ephedrae Herba)were also included.At the same time,4 core drug pairs such as"Shengshigao(Gypsum Crudum)-Gancao(Glycyrrhizae Radix)"and"Shengshigao(Gypsum Crudum)-Huangqin(Scutellariae Radix)",7 new prescription combinations such as"Shengshigao(Gypsum Crudum)-Wuweizi(Schisandrae Fructus)-Zhishi(Aurantii Fructus Immaturus)-Jiegeng(Platycodonis Radix)",and 6 core drug groups such as"Shengshigao(Gypsum Crudum),Mahuang(Ephedrae Herba),Gancao(Glycyrrhizae Radix),Xingren(Armeniacae Semen),Huangqin(Scutellariae Radix),Jiegeng(Platycodonis Radix),and Chenpi(Citri Reticulatae Pericarpium)"were extracted.Moreover,18 intersection targets of"Shengshigao(Gypsum Crudum)-major TCM diseases"

关 键 词：生石膏 成方制剂 中医传承辅助平台 网络药理学 《中华人民共和国药典》 证治规律 

分 类 号：R289.5[医药卫生—方剂学]